Is it time to end 340B?
A Health Affiairs Forefront article by DiGiorgio (2023) argues the 340B has outlived its purposes. He writes: By mandating that drug companies give a large discount to covered entities, the majority of which are hospitals with disproportionate share or critical access designations, the 340B program was intended to provide a financial buffer for institutions such as the…